New York, June 16, 2026, 18:02 EDT
- Pfizer ended the day 0.15% higher at $26.04, a steadier close than the S&P 500 and Nasdaq as U.S. trading finished mixed.
- Rigel has completed the Veppanu licensing agreement with Arvinas and Pfizer, which brings a $70 million upfront payment. The payment will be shared equally between Arvinas and Pfizer.
- The stock is still linked to concern about whether Pfizer’s oncology and obesity drugs will make up for falling COVID sales and upcoming patent expirations.
Pfizer Inc. shares ticked up Tuesday after Rigel Pharmaceuticals announced it has finalized a licensing deal for Veppanu, the breast-cancer treatment Arvinas and Pfizer developed together. The move offered a small bit of news in cancer drugs for investors. Broader U.S. indexes finished the session mixed.
Dow sets a record, Pfizer edges higher as tech lags
Pfizer finished at $26.04, up 0.15%. The S&P 500 slipped 0.57% and the Nasdaq lost 1.15%. The Dow gained 0.64% for a record close, lifted as money rotated out of tech stocks into other sectors.
The deal isn’t really about the numbers up front. For Pfizer, it’s more about the story for investors now. The drugmaker is still working to show that a mix of new drugs, recent acquisitions, and late-stage pipeline bets can drive growth. The rush from COVID isn’t there anymore, and older drugs are nearing loss of exclusivity, which brings generic competition.
Rigel said the deal took effect June 11, following antitrust clearance and other needed steps. The company paid $70 million upfront, split equally between Arvinas and Pfizer, all in cash at closing. Rigel expects Veppanu to hit the market in August.
Veppanu is cleared in the U.S. for treating adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer after disease gets worse on at least one round of endocrine therapy. The drug is used when hormone-based treatments fail and the patient’s ESR1 gene has mutated.
Stocks struggled for direction as the market stayed quiet ahead of the Federal Reserve policy decision. Investors kept to the sidelines, with Janney Montgomery Scott chief investment strategist Mark Luschini telling Reuters the market was “digesting some of those gains” from Monday’s rally. Reuters
Pfizer’s (PFE) cheap stock price keeps some analysts interested, but the Street wants firmer signs from its drug pipeline. RBC Capital’s Trung Huynh moved the stock up to Sector Perform from Underperform last week, citing a “more balanced” risk-reward. Huynh is looking to two major clinical updates coming in 2026, but left his price target at $25. StreetInsider.com
After Pfizer’s first-quarter numbers, the same tension resurfaced. J.P. Morgan’s Chris Schott said drugs in the pipeline “could make the story more interesting over time,” but said sentiment would not pick up unless there was more data and less risk. RBC’s Huynh was more direct, calling Pfizer a “catalyst story, not an earnings story.” Reuters
Pfizer is pushing investors to focus on its obesity efforts as rivals Eli Lilly and Novo Nordisk lead the field. This month the company said its Phase 2b results back moving berobenatide, a GLP-1 receptor agonist, into Phase 3 obesity studies. The drug type mimics a hormone used in diabetes and obesity treatments. Jim List at Pfizer said the drug gave “continuous, uninterrupted weight loss” in selected studies heading into Phase 3. Pfizer
Pfizer’s main business still comes from its wide range of drugs, like Eliquis, a blood thinner it sells with Bristol Myers Squibb. Pfizer reported first-quarter revenue at $14.5 billion, up 2% on an operational basis. Sales of launched and acquired products rose 22%. CFO David Denton said the company is sticking to its full-year 2026 guidance.
MarketScreener lists 29 analysts on the name with an average Outperform and a target of $29.19, about 12% over the last close. Price targets run from $24 up to $36, showing the trade-off: income and possible pipeline upside against slow growth and patent headwinds.
But there’s risk on the downside too. Rigel flagged that Veppanu’s launch needs transfer work to go well, plus strong doctor adoption, real patient demand, positive reimbursement, the right pricing, limited competition, OK regulatory outcomes and tolerable side effects; if those fall short or if Pfizer’s pipeline trials disappoint, the stock could end up relying on more cost cuts and the dividend instead of growth.
